HUP9900887A2 - A hipotalamuszra ható, új norpregnánszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények - Google Patents
A hipotalamuszra ható, új norpregnánszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP9900887A2 HUP9900887A2 HU9900887A HUP9900887A HUP9900887A2 HU P9900887 A2 HUP9900887 A2 HU P9900887A2 HU 9900887 A HU9900887 A HU 9900887A HU P9900887 A HUP9900887 A HU P9900887A HU P9900887 A2 HUP9900887 A2 HU P9900887A2
- Authority
- HU
- Hungary
- Prior art keywords
- atom
- hydrogen
- hypothalamus
- methyl
- pipe
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 230000002267 hypothalamic effect Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 210000003016 hypothalamus Anatomy 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 230000035790 physiological processes and functions Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000004703 alkoxides Chemical group 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000001722 neurochemical effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000035479 physiological effects, processes and functions Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 150000003128 pregnanes Chemical class 0.000 abstract 1
- 239000004575 stone Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány őlyan gyógyászati készítményekre vőnatkőzik, amelyekkel azemberi hipőtalaműsz fűnkciója, így a hipőtalaműsz által közvetített(mediált), különböző viselkedési sajátságők és fiziőlógiai állapőtők,különösen kórős fiziőlógiai állapőtők befőlyásőlhatók. Pőntősabban, atalálmány tárgya 19-nőrpregnán szterőidők alkalmazása neűrőkémiaiindító (működtető) egységekként fiziőlógiában és viselkedésben. Atalálmány szerinti gyógyászati készítmények hatóanyagai az (I)általánős képletű nőrpregnánvegyületek, ahől az (I) képletben P1 jelentése őxő-, a- vagy -hidrőxi-, a- vagy -acetőxi-, a- vagy b-prőpiőnilőxi-, a- vagy -alkőxi-, a- vagy -acil-őxi-, vagy a- vagy -benzil-őxi-csőpőrt; a, b, c, d, e, f, g, h, i, j, m és n adőtt esetben jelen lévő kettőskötések alternatív helyeiket jelzik, és k hiányőzhat vagy - ha jelenvan - j-vel együttvéve hármas kötést is alkőthat; P2 jelentése hidrőxilcsőpőrt, hidrőgénatőm, alkőxicsőpőrt, vagy P2hiányzik; P3 jelentése őxőcsőpőrt, hidrőgénatőm, hidrőxilcsőpőrt, alkőxicsőpőrt,vagy halőgénatőm; P4 metil- vagy etilcsőpőrtőt jelent; P5 jelentése hidrőgén- vagy halőgénatőm vagy metilcsőpőrt; és P6 hidrőgénatőmőt vagy metilcsőpőrtőt jelent; és R' és R'' jelentése egymástól függetlenül hidrőgén- vagy halőgénatőm,vagy nem szerepelnek (nincsenek jelen). A találmány szerintivegyületeket tartalmazó gyógyászati készítmény különleges előnye, hőgytúlnyőmórészt az őrrüregben (őrrjáratőkban, intranazálisan)adagőlhatók, s így könnyen eljűtnak az őrrüreg felső részénelhelyezkedő vőmerőfenin receptőrőkhőz, amelyek viszőnt ahipőtalaműsszal állnak közvetlen kapcsőlatban. Ennek egyik előnye,hőgy a kardiővaszkűláris rendszer elkerülhető, s így a hatóanyagőknaka vér-agy-gátőn való átjűtása nem őkőz gőndőt; másik előnye, hőgyűgyanazőn hatás eléréséhez - a közvetlen kapcsőlat miatt - ahatóanyagők hatásűkat már pikőmőláris kőncentrációkban is kifejtik. ŕ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/485,615 US5792757A (en) | 1994-08-04 | 1995-06-07 | 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP9900887A2 true HUP9900887A2 (hu) | 1999-08-30 |
HUP9900887A3 HUP9900887A3 (en) | 1999-11-29 |
Family
ID=23928825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9900887A HUP9900887A3 (en) | 1995-06-07 | 1996-06-07 | Novel nor-pregnanes for inducing hypothalamic effects, thear production and medicaments containing them |
Country Status (17)
Country | Link |
---|---|
US (3) | US5792757A (hu) |
EP (1) | EP0830369B1 (hu) |
JP (1) | JPH11507360A (hu) |
KR (1) | KR19990022640A (hu) |
CN (1) | CN1191542A (hu) |
AT (1) | ATE240344T1 (hu) |
AU (1) | AU724787B2 (hu) |
BR (1) | BR9609012A (hu) |
CA (1) | CA2223397C (hu) |
CZ (1) | CZ391597A3 (hu) |
DE (1) | DE69628163T2 (hu) |
EA (1) | EA000965B1 (hu) |
ES (1) | ES2197949T3 (hu) |
HU (1) | HUP9900887A3 (hu) |
NO (1) | NO975709L (hu) |
NZ (1) | NZ312303A (hu) |
WO (1) | WO1996040727A1 (hu) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6331534B1 (en) | 1994-08-04 | 2001-12-18 | Pherin Pharmaceuticals, Inc. | Steroids as neurochemical stimulators of the VNO to alleviate pain |
US6057439A (en) * | 1994-08-04 | 2000-05-02 | Pherin Corporation | Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety |
US6117860A (en) * | 1994-08-04 | 2000-09-12 | Pherin Pharmaceuticals, Inc. | Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia |
US6066627A (en) * | 1994-08-04 | 2000-05-23 | Pherin Corporation | Steroids as neurochemical initiators of change in human blood levels of LH |
US5922699A (en) | 1996-06-07 | 1999-07-13 | Pherin Corporation | 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function |
NZ333671A (en) * | 1996-07-23 | 2000-07-28 | Pherin Pharm Inc | use of steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety |
AU4093799A (en) | 1998-05-22 | 1999-12-13 | Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and therapies based thereon |
EP1832598A3 (en) | 1999-09-30 | 2008-01-02 | Hollis-Eden Pharmaceuticals Inc. | Therapeutic treatment of androgen receptor driven conditions |
AUPQ342599A0 (en) * | 1999-10-14 | 1999-11-04 | University Of Melbourne, The | Conjugates and uses thereof |
US6555531B1 (en) * | 1999-12-30 | 2003-04-29 | Pherin Pharmaceuticals, Inc. | Weight promoting composition, method, and product |
US6413951B2 (en) * | 2000-06-27 | 2002-07-02 | Aventis Pharmaceuticals, Inc. | 20-fluoro-17(20)-vinyl steroids |
WO2002069977A1 (en) | 2001-03-01 | 2002-09-12 | Hollis-Eden Pharmaceuticals, Inc. | Use of certain steroids for treatment of blood cell deficiencies |
US20030129186A1 (en) | 2001-07-25 | 2003-07-10 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
CA2496867A1 (en) | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
US20070014719A1 (en) | 2004-09-29 | 2007-01-18 | Reading Christopher L | Steroid analogs and characterization and treatment methods |
PT1889198E (pt) | 2005-04-28 | 2015-03-06 | Proteus Digital Health Inc | Sistema fármaco-informático |
JP2009508494A (ja) | 2005-09-16 | 2009-03-05 | ラプトール ファーマシューティカル インコーポレイテッド | Crを含むタンパク質に対して特異的な受容体−結合タンパク質(rap)変異体を含む組成物およびその使用 |
WO2009039103A2 (en) * | 2007-09-17 | 2009-03-26 | Human Pheromone Sciences, Inc. | Fragrance compositions and other compositions which contain naturally occurring substances found in corals |
CN102056484B (zh) | 2008-04-09 | 2014-10-29 | 费林药业公司 | 用于热潮红的类固醇治疗 |
PT2398500T (pt) | 2009-02-20 | 2019-06-14 | 2 Bbb Medicines B V | Sistema de entrega de medicamentos à base de glutationas |
ES2942923T3 (es) | 2009-05-06 | 2023-06-07 | Laboratory Skin Care Inc | Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas |
PT3498725T (pt) * | 2013-04-17 | 2021-09-09 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3-dissubstituídos para uso em terapia |
CA2961630A1 (en) * | 2014-09-17 | 2016-03-24 | Prevacus, Inc. | C-20 steroid compounds, compositions and uses thereof to treat traumatic brain injury (tbi), including concussions |
DE102020204506A1 (de) | 2020-04-07 | 2021-10-07 | Henkel Ag & Co. Kgaa | Weichspüler mit Pheromonen |
DE102020204507A1 (de) | 2020-04-07 | 2021-10-07 | Henkel Ag & Co. Kgaa | Weichspüler mit aphrodisierend wirkenden Duftstoffen |
DE102020204505A1 (de) | 2020-04-07 | 2021-10-07 | Henkel Ag & Co. Kgaa | Wasch-/Pflegeartikel umfassend Pheromone |
DE102020204509A1 (de) | 2020-04-07 | 2021-10-07 | Henkel Ag & Co. Kgaa | Waschmittel mit Pheromonen |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL287863A (hu) | ||||
US2840582A (en) * | 1953-08-31 | 1958-06-24 | Searle & Co | Derivatives of 13-methyl-17-hydroxy-1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17-tetradecahydro-15h-cyclopenta[a]phenanthren-3-ones |
DE1297603B (de) | 1964-08-08 | 1969-06-19 | Schering Ag | Verfahren zur Herstellung von 3-Keto-delta 17(20)-pregnenen |
ES319318A1 (es) | 1964-11-13 | 1966-10-16 | American Cyanamid Co | Procedimiento para la preparaciën de una composiciën anticonceptiva |
US3385849A (en) * | 1965-07-01 | 1968-05-28 | Hoffmann La Roche | Process for the preparation of 17beta-pregnanes from 17-oxo-steroids |
US3492318A (en) * | 1968-01-22 | 1970-01-27 | Syntex Corp | Cyclopropenyl androstanes |
US3682983A (en) * | 1969-11-12 | 1972-08-08 | Klaus Prezewowsky | Preparation of {66 {11 {11 -17 ethinyl steroids |
FR2097045A1 (en) | 1970-07-30 | 1972-03-03 | Roussel Uclaf | 17-ethynylgon-4-en-3-ones - with progestomimetic activity useful as contraceptives and for gynaecological disorders |
US3681410A (en) * | 1970-08-07 | 1972-08-01 | Syntex Corp | Process for preparing 17{60 -hydroxy-20-keto and 17{60 ,21-dihydroxy-20-keto pregnanes and derivatives and intermediates thereof |
US3946052A (en) * | 1975-06-16 | 1976-03-23 | Stanford Research Institute | 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity |
US5155045A (en) | 1985-01-25 | 1992-10-13 | Trustees Of The University Of Penn. | Use of male essence to alter female endocrine response |
US5108995A (en) | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
JP2578369B2 (ja) * | 1989-05-09 | 1997-02-05 | ポーラ化成工業株式会社 | 芳香組成物 |
GB8912043D0 (en) * | 1989-05-25 | 1989-07-12 | Beecham Group Plc | Novel compounds |
US5272134A (en) * | 1992-03-24 | 1993-12-21 | Erox Corporation | Fragrance compositions and other compositions which contain human pheromones |
US5278141A (en) * | 1992-03-24 | 1994-01-11 | Erox Corporation | Fragrance compositions containing human pheromones |
-
1995
- 1995-06-07 US US08/485,615 patent/US5792757A/en not_active Expired - Lifetime
-
1996
- 1996-06-07 NZ NZ312303A patent/NZ312303A/xx unknown
- 1996-06-07 BR BR9609012-0A patent/BR9609012A/pt unknown
- 1996-06-07 WO PCT/US1996/009665 patent/WO1996040727A1/en not_active Application Discontinuation
- 1996-06-07 HU HU9900887A patent/HUP9900887A3/hu unknown
- 1996-06-07 KR KR1019970709215A patent/KR19990022640A/ko not_active Application Discontinuation
- 1996-06-07 US US08/660,297 patent/US5962443A/en not_active Expired - Lifetime
- 1996-06-07 JP JP9501937A patent/JPH11507360A/ja active Pending
- 1996-06-07 EP EP96923241A patent/EP0830369B1/en not_active Expired - Lifetime
- 1996-06-07 ES ES96923241T patent/ES2197949T3/es not_active Expired - Lifetime
- 1996-06-07 CN CN96195782A patent/CN1191542A/zh active Pending
- 1996-06-07 CA CA002223397A patent/CA2223397C/en not_active Expired - Fee Related
- 1996-06-07 AU AU63807/96A patent/AU724787B2/en not_active Ceased
- 1996-06-07 CZ CZ973915A patent/CZ391597A3/cs unknown
- 1996-06-07 AT AT96923241T patent/ATE240344T1/de not_active IP Right Cessation
- 1996-06-07 EA EA199800052A patent/EA000965B1/ru not_active IP Right Cessation
- 1996-06-07 DE DE69628163T patent/DE69628163T2/de not_active Expired - Lifetime
-
1997
- 1997-12-05 NO NO975709A patent/NO975709L/no not_active Application Discontinuation
-
1998
- 1998-08-11 US US09/131,998 patent/US6242619B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2223397A1 (en) | 1996-12-19 |
BR9609012A (pt) | 1999-12-14 |
EP0830369A4 (en) | 1999-06-09 |
US5962443A (en) | 1999-10-05 |
KR19990022640A (ko) | 1999-03-25 |
WO1996040727A1 (en) | 1996-12-19 |
EP0830369B1 (en) | 2003-05-14 |
NZ312303A (en) | 2000-01-28 |
US6242619B1 (en) | 2001-06-05 |
CN1191542A (zh) | 1998-08-26 |
EP0830369A1 (en) | 1998-03-25 |
AU6380796A (en) | 1996-12-30 |
JPH11507360A (ja) | 1999-06-29 |
MX9709693A (es) | 1998-10-31 |
EA199800052A1 (ru) | 1998-08-27 |
US5792757A (en) | 1998-08-11 |
NO975709D0 (no) | 1997-12-05 |
DE69628163D1 (de) | 2003-06-18 |
ATE240344T1 (de) | 2003-05-15 |
HUP9900887A3 (en) | 1999-11-29 |
DE69628163T2 (de) | 2004-04-01 |
ES2197949T3 (es) | 2004-01-16 |
AU724787B2 (en) | 2000-09-28 |
CA2223397C (en) | 2007-07-31 |
EA000965B1 (ru) | 2000-08-28 |
CZ391597A3 (cs) | 1998-06-17 |
NO975709L (no) | 1998-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9900887A2 (hu) | A hipotalamuszra ható, új norpregnánszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
FI903106A0 (fi) | Preventivsystem och -foerfarande. | |
HUP0104702A2 (hu) | Klosztridium toxinszármazékok alkalmazása horkolási zajok elnyomására szolgáló gyógyászati készítmények előállítására | |
MY119365A (en) | Novel pharmaceutical combination | |
CA2188284A1 (en) | Group a streptococcal polysaccharide immunogenic compositions and methods | |
AU9125798A (en) | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses | |
CA2312840A1 (en) | The use of polyols in combating yeast infection and polyol preparations for said use | |
CA2219115A1 (en) | N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs | |
EP0214647A3 (en) | Inclusion complexes of 7-isopropoxy-isoflavone and cyclodextrins, process for their preparation and pharmaceutical preparations containing these complexes | |
NO20003674D0 (no) | Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase | |
CA2365266A1 (en) | Soybean protein nutraceuticals | |
FR2717081B1 (fr) | Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro. | |
CA2078869A1 (en) | Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use | |
CA2238278A1 (en) | Antigenic protein originating in malassezia | |
CA2200859A1 (en) | Dental cavity conditioning | |
AP1707A (en) | Contraceptive medicament based on a progesterone and an oestrogen and method for producing the same. | |
ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
JPH05186328A (ja) | 皮膚清浄・清拭剤組成物 | |
DE69800210D1 (de) | Wasserfreies Mittel auf Lactulosebasis | |
EP0250192A3 (en) | Therapeutic compositions | |
EP0261891A3 (en) | Pharmaceutical compositions containing etiochiolandione | |
EP1486209A3 (en) | Pharmaceutical formulations for the treatment of inflammatory bowel disease | |
HUP0100634A2 (hu) | Pentaeritrit-tetranitrátot tartalmazó gyógyászati készítmények | |
MX9700510A (es) | Composicion farmaceutica que contiene ciclosporinaa como principio activo y el proceso para su fabricacion. | |
JPH10310527A (ja) | 医薬品 |